Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Barthe Y, Thabut D, Guyader D, Hezode C, Picon M, Causse X, Leroy V, Bronowicki JP, Carrieri P, Riachi G, Rosa I, Attali P, Molina JM, Bacq Y, Tran A, Grangé JD, Zoulim F, Fontaine H, Alric L, Bertucci I, Bouvier-Alias M, Carrat F; ANRS HB06 PEGAN Study Group. Bourlière M, et al. Among authors: guyader d. Lancet Gastroenterol Hepatol. 2017 Mar;2(3):177-188. doi: 10.1016/S2468-1253(16)30189-3. Epub 2017 Jan 20. Lancet Gastroenterol Hepatol. 2017. PMID: 28404133 Free article. Clinical Trial.
Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients.
Boucher E, Guyader D, Jacquelinet S, Andre P, Mendler MH, Turlin B, Canva V, Nousbaum JB, Bernard PH, Nouel O, Raabe JJ, Dao T, Gasser P, Verger P, Boutin J, Bergerault P, Joram F, Colmar P, Messner M, Brissot P, Deugnier Y. Boucher E, et al. Among authors: guyader d. Dig Liver Dis. 2000 Jan-Feb;32(1):29-33. doi: 10.1016/s1590-8658(00)80041-9. Dig Liver Dis. 2000. PMID: 10975752 Clinical Trial.
[Maintenance therapy for chronic hepatitis C].
Trépo C, Marion-Audibert AM, Samuel D, Guyader D, Fontanges T. Trépo C, et al. Among authors: guyader d. Gastroenterol Clin Biol. 2007 Aug-Sep;31(8-9 Pt 3):4S29-33. Gastroenterol Clin Biol. 2007. PMID: 17965632 Free article. Review. French.
Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection.
Calès P, Halfon P, Batisse D, Carrat F, Perré P, Penaranda G, Guyader D, d'Alteroche L, Fouchard-Hubert I, Michelet C, Veillon P, Lambert J, Weiss L, Salmon D, Cacoub P. Calès P, et al. Among authors: guyader d, d alteroche l. J Hepatol. 2010 Aug;53(2):238-44. doi: 10.1016/j.jhep.2010.03.007. Epub 2010 Apr 18. J Hepatol. 2010. PMID: 20493576 Free article.
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
Forestier N, Larrey D, Guyader D, Marcellin P, Rouzier R, Patat A, Smith P, Bradford W, Porter S, Blatt L, Seiwert SD, Zeuzem S. Forestier N, et al. Among authors: guyader d. J Hepatol. 2011 Jun;54(6):1130-6. doi: 10.1016/j.jhep.2010.11.001. Epub 2011 Feb 24. J Hepatol. 2011. PMID: 21145848 Clinical Trial.
179 results